Back to top

Analyst Blog

AstraZeneca (AZN - Analyst Report) recently announced that the company has created seven positions in the senior executive team. At the same time, two senior roles were discontinued.

We note that three of the seven newly created positions are aimed at the discovery and development of candidates (including small molecules and biologics). The other three positions were created with region-wise (North America, Europe and International) focus. A position for management of global portfolio and product strategy was also created.

The two positions, which were terminated, were President of Research and Development, and Executive Vice President, Global Commercial.

We remind investors that last year Pascal Soriot was recruited as the Chief Executive Officer (CEO) of AstraZeneca. He is heading the company since Sep 1, 2012.

We believe that the leadership change will benefit AstraZeneca. It reflects the company’s efforts to advance and boost its pipeline with increased focus on research and development.

We remain concerned about the generic competition that AstraZeneca is currently facing or expects to face for its various drugs. This has put significant pressure on the company. Additionally, there is increasing uncertainty regarding the company’s key drug Crestor (cholesterol management) due to the entry of generic versions of Pfizer’s (PFE - Analyst Report) Lipitor in Nov 2011. The company’s much hyped antiplatelet, Brilinta’s performance has remained lukewarm.

AstraZeneca is looking to combat the generic threat through deals and acquisitions. The Ardelyx and Isis Pharma agreements, Ardea acquisition, the collaboration with Amgen (AMGN - Analyst Report) and the expansion of the diabetes alliance with Bristol-Myers Squibb (BMY - Analyst Report) represent efforts in that direction.

We currently have a Neutral recommendation on AstraZeneca. The stock carries a Zacks Rank #3 (Hold) in the short run.

Large-cap pharma companies that currently look more attractive include Johnson & Johnson’s (JNJ - Analyst Report), Novartis (NVS - Analyst Report) and Sanofi (SNY - Analyst Report). All three companies carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%